Navigation Links
How can policymakers cope with ambiguity?
Date:2/25/2010

How might policymakers make reasonable decisions when they have limited information?

That's the question Northwestern University's Charles F. Manski explores in his new paper, "Vaccination With Partial Knowledge of External Effectiveness." The paper is published online by the Proceedings of the National Academy of Sciences (PNAS) at http://www.pnas.org/content/early/2010/02/05/0915009107.full.pdf+html.

"Let's say you're a public health official from the Centers for Disease Control, and you don't really know how much disease is going to be averted by vaccinating different fractions of the population," said Manski, the Board of Trustees Professor in Economics in the Weinberg College of Arts and Sciences. "Then how should you choose a policy? That's really what the paper tries to address."

In his paper, Manski sets up the following scenario: "You can look back over the last year and say we vaccinated 30 percent of the population, and this is what happened. But the question you want to answer is whether 30 percent is a good fraction to vaccinate [from a public health perspective] because you don't observe what would have happened if last year you had vaccinated 40 percent, 20 percent or 80 percent."

In this case, Manski, whose research spans econometrics, judgment and decision, and the analysis of social policy, said there are at least two sources of partial knowledge. First, the policymaker may only partially know how effective the vaccination will be in generating an immune response. Second, the policymaker may only partially know how effective the vaccination will be in preventing transmission of the disease to members of the public.

Applying ideas developed in research on decision-making under ambiguity, Manski recommends that the planner or policymaker first determine which vaccination rates are inferior and eliminate them. Focusing on the remaining possibilities, Manski then shows what vaccination rate the planner should choose if he applies one of two decision criteria. Both criteria protect the planner from poor outcomes, but in different ways.

Manski became interested in vaccination policy in light of H1N1. However, he said his paper is more relatable to a disease that occurs in the same way every year, like the regular seasonal flu, measles or mumps. Not enough is known about H1N1 to have long-term observable data. "If we get H1N1 next year, what I did in this paper would become more relevant," he said.

Manski said the issue of making public policy with limited information applies to many other issues that are currently in the headlines.

"Take one that's very controversial today global warming," he said. "We have limited information on what exactly is happening. There's a lot of disagreement, and yet we have to make some decisions now."


'/>"/>

Contact: Hilary Hurd Anyaso
h-anyaso@northwestern.edu
847-491-4887
Northwestern University
Source:Eurekalert

Related medicine news :

1. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
2. Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention
3. Kidney Care Partners Encourages Policymakers to Support Increased Kidney Care Education and Disease Prevention Programs
4. Susan G. Komen for the Cure(R) Calls on Policymakers to Address Unfairness in Breast Cancer Incidence and Mortality
5. Time for Policymakers to Choose: Prompt Pay Mandate or Postpone AMP Reimbursement Cuts
6. Home Health Leaders Launch Alliance to Sponsor Research and to Educate Public and Policymakers on Sectors Contributions to National Health Reform
7. U.S. Healthcare Efficiency Index(TM) Expands Advisory Council; Calls on Policymakers to Act on Billions in Administrative Waste
8. Homecare Associations Nationwide Urge Policymakers to Rescind Controversial Medicare Competitive Bidding Rule
9. 84 Members of Congress, Led by Rep. Betty Sutton, Urge Policymakers to Rescind Controversial Medicare Competitive Bidding Rule Before April 18 Deadline
10. Policymakers, Experts, Public Agree: Physical Activity Plan Needed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: